Compare iShares International Treasury Bond ETF (IGOV) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs McKesson Corporation — how do they compare? iShares International Treasury Bond ETF trades at $41.21, while McKesson Corporation trades at $884.91 (market cap $105.14B). The key difference: McKesson Corporation pays a 0.42% dividend while iShares International Treasury Bond ETF pays none, and McKesson Corporation is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IGOV | MCK | |
|---|---|---|
52-Week High | $43.09 | $995.69 |
52-Week Low | $40.35 | $659.01 |
Market Cap | — | $105.14B |
Sector | — | Health |
Enterprise Value | — | $111.67B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV, an iShares International Treasury Bond ETF, trades at $41.21, showing minimal daily movement with a 0.05% gain. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights significant downside risk due to its high duration exposure amid global inflationary pressures and geopolitical tensions, which could lead to capital losses as benchmark rates rise.
The outlook for IGOV is clouded by macroeconomic headwinds; rising global interest rates pose a substantial risk to its bond holdings. Investment opportunity exists for those seeking international treasury exposure, but caution is warranted due to sensitivity to rate changes and ongoing energy-related market volatility.
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
